FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway

Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.